Topic: COMP360

Recent findings suggest that COMP360 (Compass Pathways’ investigational proprietary formulation of synthetic psilocybin) modulates negative affective biases in a rat model. Based on our current behavioural data, the mechanism is hypothesised to depend on psilocin, the active metabolite of psilocybin, acting as a partial agonist at both 5-HT2A and 5-HT1A receptors and altering neuronal activity, particularly in circuits which regulate affect and include the medial prefrontal cortex (mPFC). In the present study, we investigated effects of acute psilocin on stimulus-evoked excitatory postsynaptic